[Clinical experimentation with a new antihistaminic molecule in allergic conjunctivitis].
Current pathogenetic and symptomatological knowledge of allergic conjunctivitis and its treatment with a recently synthesised antihistaminic molecule, Astemizole, is reported.
D000293:Adolescent; D000328:Adult; D016589:Astemizole; D001562:Benzimidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D003233:Conjunctivitis, Allergic / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006634:Histamine H1 Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D013997:Time Factors
D001562:Benzimidazoles; D006634:Histamine H1 Antagonists; D016589:Astemizole
Sperimentazione clinica con una nuova molecola antistaminica nelle congiuntiviti allergiche.